Publication of the activity report and financial information for the first half-year (April – Sept. 2019) December 3, 2019 December 3, 2019
The MedinCell General Meeting votes to include the “Raison d’être” of the Company in its articles of association September 10, 2019 September 10, 2019
MedinCell receives a new grant to develop a best-in-class long-acting injectable product for HIV PrEP September 4, 2019 September 4, 2019
MedinCell partners to address the untapped financial potential in Animal Health August 28, 2019 August 28, 2019
Long-acting injectable antipsychotic using MedinCell’s technology receives FDA IND clearance to initiate clinical activities August 26, 2019 August 26, 2019
Third long-acting injectable antipsychotic using MedinCell’s technology enters preclinical development July 9, 2019 July 9, 2019
Shareholders audioconference and publication of the results for the 2018-2019 financial year, on June 4, 2019 May 22, 2019 May 22, 2019
MedinCell demonstrates in vivo the efficacy of the first injectable combining surgical anesthesia and 3 days opioid free postoperative pain management March 11, 2019 March 11, 2019
MedinCell receives funding for the second formulation phase of its 6-month injectable contraceptive January 24, 2019 January 24, 2019
